P1, N=101, Recruiting, Suzhou Abogen Biosciences Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029

P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P1/2, N=5, Completed, National Cancer Institute (NCI) | N=70 --> 5 | Recruiting --> Completed

P1, N=101, Not yet recruiting, Suzhou Abogen Biosciences Co., Ltd.

P1, N=237, Active, not recruiting, Quanta Therapeutics | Recruiting --> Active, not recruiting

P1, N=32, Not yet recruiting, Zhejiang Cancer Hospital; Shanghai Ruihongdi Pharmaceutical Co., LTD

P1, N=47, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed

P1, N=188, Recruiting, Alterome Therapeutics, Inc. | N=130 --> 188

P1, N=27, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Aug 2025 --> Jun 2027 | Trial primary completion date: Aug 2025 --> Jun 2027

These results indicate that targeting the NF-κB pathway may represent a promising therapeutic strategy to attenuate HGF- induced resistance to KRAS G12C inhibitors in lung adenocarcinoma.

In this study, we evaluated the efficacy, in terms of cell viability and volumetric reduction, of adding KRAS inhibitors (KRASi) sequentially or concurrently to CT in both parental (PR) and gemcitabine-resistant (GR) KRAS mutated NSCLC cell lines (SW1573 and H23)...Interestingly, in the 3D model, the concomitant use of KRASi+CT reduced spheroid volume in both PR and GR spheroids. Our results indicate that KRASi enhances the efficacy of CT in both NSCLC PR and GR cells, suggesting a potential therapeutic strategy to overcome chemoresistance in the adjuvant setting of NSCLC.